Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; and HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York. more
Time Frame | HOTH | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.4% | -2.12% | 0.77% |
1-Month Return | -5.04% | -2.54% | 2.65% |
3-Month Return | -21.08% | -6.28% | 12.3% |
6-Month Return | -25.96% | -1.36% | 13.48% |
1-Year Return | -32.53% | 9.29% | 33.47% |
3-Year Return | -95.47% | 10.05% | 32.22% |
5-Year Return | -99.24% | 43.69% | 92.85% |
10-Year Return | -99.61% | 103.1% | 194.31% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 31.62K | 25.87K | 46.87M | 66.83K | - | [{"date":"2019-12-31","value":0.07,"profit":true},{"date":"2020-12-31","value":0.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.14,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | (31.62K) | (25.87K) | (46.87M) | (66.83K) | - | [{"date":"2019-12-31","value":-3162200,"profit":false},{"date":"2020-12-31","value":-2587100,"profit":false},{"date":"2021-12-31","value":-4687100000,"profit":false},{"date":"2022-12-31","value":-6683400,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | - | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 7.71M | 7.30M | 14.10M | 11.07M | 7.69M | [{"date":"2019-12-31","value":54.71,"profit":true},{"date":"2020-12-31","value":51.78,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":78.47,"profit":true},{"date":"2023-12-31","value":54.55,"profit":true}] |
Operating Income | (7.71M) | (7.30M) | (14.10M) | (11.07M) | (7.69M) | [{"date":"2019-12-31","value":-771499700,"profit":false},{"date":"2020-12-31","value":-730197400,"profit":false},{"date":"2021-12-31","value":-1410144000,"profit":false},{"date":"2022-12-31","value":-1106555400,"profit":false},{"date":"2023-12-31","value":-769224200,"profit":false}] |
Total Non-Operating Income/Expense | 10.39K | - | (212.26K) | (300.03K) | (152.37K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-2043.76,"profit":false},{"date":"2022-12-31","value":-2888.78,"profit":false},{"date":"2023-12-31","value":-1467.04,"profit":false}] |
Pre-Tax Income | (7.70M) | (7.20M) | (14.31M) | (11.37M) | (7.85M) | [{"date":"2019-12-31","value":-770463600,"profit":false},{"date":"2020-12-31","value":-719781600,"profit":false},{"date":"2021-12-31","value":-1431370500,"profit":false},{"date":"2022-12-31","value":-1137195300,"profit":false},{"date":"2023-12-31","value":-784539000,"profit":false}] |
Income Taxes | (10.36K) | (205.25K) | 212.26K | 305.41K | (7.69K) | [{"date":"2019-12-31","value":-3.39,"profit":false},{"date":"2020-12-31","value":-67.21,"profit":false},{"date":"2021-12-31","value":69.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-2.52,"profit":false}] |
Income After Taxes | (7.69M) | - | (14.53M) | (11.68M) | (7.84M) | [{"date":"2019-12-31","value":-769427500,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1452597000,"profit":false},{"date":"2022-12-31","value":-1167736200,"profit":false},{"date":"2023-12-31","value":-783769776,"profit":false}] |
Income From Continuous Operations | (7.70M) | (7.20M) | (14.31M) | (11.37M) | (9.62M) | [{"date":"2019-12-31","value":-770463600,"profit":false},{"date":"2020-12-31","value":-719781600,"profit":false},{"date":"2021-12-31","value":-1431370500,"profit":false},{"date":"2022-12-31","value":-1137195300,"profit":false},{"date":"2023-12-31","value":-962174300,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (7.69M) | (7.20M) | (14.31M) | (11.68M) | (7.85M) | [{"date":"2019-12-31","value":-769427500,"profit":false},{"date":"2020-12-31","value":-719781600,"profit":false},{"date":"2021-12-31","value":-1431370500,"profit":false},{"date":"2022-12-31","value":-1167736200,"profit":false},{"date":"2023-12-31","value":-784539000,"profit":false}] |
EPS (Diluted) | (18.11) | (14.50) | (16.50) | (9.91) | (4.35) | [{"date":"2019-12-31","value":-1811,"profit":false},{"date":"2020-12-31","value":-1450,"profit":false},{"date":"2021-12-31","value":-1650,"profit":false},{"date":"2022-12-31","value":-991,"profit":false},{"date":"2023-12-31","value":-434.72,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
HOTH | |
---|---|
Cash Ratio | 9.90 |
Current Ratio | 10.16 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
HOTH | |
---|---|
ROA (LTM) | -46.16% |
ROE (LTM) | -83.41% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
HOTH | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
HOTH | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.77 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.40 |
Hoth Therapeutics Inc (HOTH) share price today is $0.8366
Yes, Indians can buy shares of Hoth Therapeutics Inc (HOTH) on Vested. To buy Hoth Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HOTH stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Hoth Therapeutics Inc (HOTH) via the Vested app. You can start investing in Hoth Therapeutics Inc (HOTH) with a minimum investment of $1.
You can invest in shares of Hoth Therapeutics Inc (HOTH) via Vested in three simple steps:
The 52-week high price of Hoth Therapeutics Inc (HOTH) is $1.73. The 52-week low price of Hoth Therapeutics Inc (HOTH) is $0.58.
The price-to-earnings (P/E) ratio of Hoth Therapeutics Inc (HOTH) is
The price-to-book (P/B) ratio of Hoth Therapeutics Inc (HOTH) is 0.77
The dividend yield of Hoth Therapeutics Inc (HOTH) is 0.00%
The market capitalization of Hoth Therapeutics Inc (HOTH) is $5.81M
The stock symbol (or ticker) of Hoth Therapeutics Inc is HOTH